A new publication referencing lanreotide appeared in the journal Cureus on August 27, 2026. The case report is titled "Carcinoid Heart Disease Presenting as Cardiogenic Shock: A Case Report." Lanreotide is an approved compound discussed in connection with this case report. The publication was indexed under PubMed ID 42801165. No specific findings, outcomes, or data from the report have been provided beyond its title, journal, and publication date. This entry serves only to note that the case report exists and has been published, without summarizing its content or conclusions. Readers interested in the full details of the case, including any clinical context or discussion involving lanreotide, should consult the original source directly. As with all publication updates, this brief reports the existence of the article rather than its results. No efficacy, safety, or causation claims are made here beyond confirming that the publication occurred on the stated date in the stated journal. For more background on lanreotide, including its approved uses and general profile, readers can refer to the compound overview.
Lanreotide Mentioned in Cureus Case Report on Carcinoid Heart Disease
See the full lanreotide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42801165/